DRRX Insider Trading

Insider Ownership Percentage: 3.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

DURECT Insider Trading History Chart

This chart shows the insider buying and selling history at DURECT by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

DURECT Share Price & Price History

Current Price: $0.80
Price Change: Price Decrease of -0.0113 (-1.40%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for DRRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.80Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for DURECT (NASDAQ:DRRX)

28.03% of DURECT stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DRRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$134kbought$367ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
DURECT logo
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Read More on DURECT

Today's Range

Now: $0.80
Low: $0.79
High: $0.81

50 Day Range

MA: $0.79
Low: $0.75
High: $0.86

52 Week Range

Now: $0.80
Low: $0.70
High: $1.88

Volume

9,019 shs

Average Volume

52,459 shs

Market Capitalization

$24.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91